Olanzapine for the Prevention of Postdischarge Nausea and Vomiting after Ambulatory Surgery: A Randomized Controlled Trial. (June 2020)

• Record Type: Journal Article
• Authors: Hyman, Jaime B.; Park, Chang; Lin, Hung-Mo; Cole, Beatriz; Rosen, Leigh; Fenske, Suzanne S.; Barr Grzesh, Rachel L.; Blank, Stephanie V.; Polsky, Sylvie B.; Hartnett, Matthew; Taub, Peter J.; Palvia, Vijay; DeMaria, Samuel; Ascher-Walsh, Charles
• Is Part Of: Anesthesiology. Volume 132:Number 6(2020)
• Publication Date: 2020-06
• Subjects: Anesthesiology -- Periodicals; Anesthetics -- Periodicals; Anesthesia -- Periodicals; 617.9605
• DOI: 10.1097/ALN.0000000000003286
• Languages: English
• ISSNs: 0003-3022

Abstract

Abstract : Background: Postdischarge nausea and vomiting after ambulatory surgery is a common problem that is not adequately addressed in current practice. This prospective, randomized, double-blind, parallel-group, placebo-controlled study was designed to test the hypothesis that oral olanzapine is superior to placebo at preventing postdischarge nausea and vomiting. Methods: In a single-center, double-blind, randomized, placebo-controlled trial, the authors compared a single preoperative dose of olanzapine 10 mg to placebo, in adult female patients 50 years old or less, undergoing ambulatory gynecologic or plastic surgery with general anesthesia. All patients received standard antiemetic prophylaxis with dexamethasone and ondansetron. The primary composite outcome was nausea and/or vomiting in the 24 h after discharge. Secondary outcomes included severe nausea, vomiting, and side effects. Results: A total of 140 patients were randomized and evaluable. The primary outcome occurred in 26 of 69 patients (38%) in the placebo group and in 10 of 71 patients (14%) in the olanzapine group (relative risk, 0.37; 95% CI, 0.20 to 0.72; P = 0.003). Severe nausea occurred in 14 patients (20%) in the placebo group and 4 patients (6%) in the olanzapine group (relative risk, 0.28; 95% CI, 0.10 to 0.80). Vomiting occurred in eight patients (12%) in the placebo group and two patients (3%) in the olanzapine group (relative risk, 0.24; 95% CI, 0.05 to 1.10). The median score for sedation (scale 0 to 10, with 10 being highest) in the 24 h after discharge was 4 (interquartile range, 2 to 7) in the placebo group and 6 (interquartile range, 3 to 8) in the olanzapine group ( P = 0.023). Conclusions: When combined with ondansetron and dexamethasone, the addition of olanzapine relative to placebo decreased the risk of nausea and/or vomiting in the 24 h after discharge from ambulatory surgery by about 60% with a slight increase in reported sedation. Abstract : The authors randomized women having day surgery to olanzapine 10 mg or placebo. All were also given both dexamethasone and ondansetron. Olanzapine reduced nausea and vomiting in the 24 h after hospital discharge from 38% to 14%, corresponding to a number-needed-to-treat of just four patients.